The Swiss voice in the world since 1935
Top stories
Stay in touch with Switzerland

Swiss parents take French drugmaker to court

Sanofi facade
Sanofi is France's largest drug manufacturer. Keystone

About a dozen Swiss parents have launched a civil action lawsuit over the prescription of the antiepileptic drug Depakine during pregnancy.


They accuse their neurologists and the French drug manufacturer Sanofi, which produces Depakine, of failing to warn them about the risks to the fetus, according to reports published on Le Matin Dimanche and SonntagsZeitung.

Depakine is still widely used today to treat epilepsy and migraines. Scientists have established that the sodium valproate contained in the drug creates psychomotor, cognitive and mental development disorders in 30 to 40% of cases.

The Swiss expecting mothers were not made aware of these dangers. A warning from agency for therapeutic products, Swissmedic, came to late.

In Switzerland, 39 children have been born with brain damage in connection to Depakine use, according to a report commissioned by the government.

Thierry Buclin, a professor of clinical pharmacology at the University Hospital of Lausanne suspects the actual figure is much higher.

The professors, who was quoted in the media reports, says the government study is incomplete. It does not consider the transgenerational effect of Depakin which has been brought to light by recent scientific studies.

The controversial drug has been authorised in Switzerland since the 1970s. Such side effects were not mentioned in the package leaflet until 2015.

In neighbouring France, as many as 6,500 children have been negatively affected by Depakine. The victims launched a collective action against Sanofi at the end of 2016 to obtain compensation.

The first complaint was made in Switzerland in 2017 by a woman who had been using the drug since adolescence and even had her dosage raised by her neurologist during one of her pregnancies. She gave birth to two children who suffer from severe cognitive disorders and autism.

Popular Stories

Most Discussed

News

The federal government is working on a new Swiss identity card with a chip

More

New Swiss biometric ID card planned for 2026

This content was published on A biometric Swiss identity card (ID) is expected to be available in Switzerland by the end of 2026. The Federal Office of Police and its federal and cantonal partners are working on a new ID card that features a chip.

Read more: New Swiss biometric ID card planned for 2026
Opportunities for social mobility remain high in Switzerland

More

Swiss continue to enjoy high social mobility, study shows

This content was published on Opportunities for upward social mobility have remained intact in Switzerland since the 1980s. Social mobility is exceptionally high by international comparison, a study shows.

Read more: Swiss continue to enjoy high social mobility, study shows
UBS launches another billion share buyback programme

More

UBS launches buyback scheme for up to $2 billion in shares

This content was published on UBS is starting a share buyback programme for up to $2 billion (CHF1.6 billion) in shares, in line with a plan approved at its annual general meeting (AGM) in April, the Swiss bank said on Monday.

Read more: UBS launches buyback scheme for up to $2 billion in shares

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR